Inhibitors of BACE for treating Alzheimer's disease: a fragment-based drug discovery story

This publication has 46 references indexed in Scilit:

• Discovery of AZD3839, a Potent and Selective BACE1 Inhibitor Clinical Candidate for the Treatment of Alzheimer Disease
  Journal of Biological Chemistry, 2012
• Experiences in fragment-based drug discovery
  Trends in Pharmacological Sciences, 2012
• Structure based design of iminohydantoin BACE1 inhibitors: Identification of an orally available, centrally active BACE1 inhibitor
  Bioorganic & Medicinal Chemistry Letters, 2012
• Aminoimidazoles as BACE-1 inhibitors: The challenge to achieve in vivo brain efficacy
  Bioorganic & Medicinal Chemistry Letters, 2012
• Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor
  Journal of Neuroscience, 2011
• Triazole-linked reduced amide isosteres: An approach for the fragment-based drug discovery of anti-Alzheimer’s BACE1 inhibitors
  Bioorganic & Medicinal Chemistry Letters, 2011
• Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model
  Bioorganic & Medicinal Chemistry Letters, 2010
• Defining Desirable Central Nervous System Drug Space through the Alignment of Molecular Properties, in Vitro ADME, and Safety Attributes
  ACS Chemical Neuroscience, 2010
• Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics
  Bioorganic & Medicinal Chemistry Letters, 2009
• Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase
  Molecular and Cellular Neuroscience, 1999